Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

August 2021 Issue of The Medicine Maker

We take a deep dive into the cell therapy sector in our cover feature and ask what progress is being made in the fight against solid tumors. Meanwhile in NextGen, researchers from Carnegie Mellon University explain how AI can be used to source new pharmaceutical compounds derived from natural sources. Pierre Bourdage, Global Head of Biopharmaceuticals at Sandoz, also gives his take on the future of biosimilars, in Business. We also sit down with Andrew Moore, who tells us how he has used his military experience to inform his approach to leadership in the pharmaceutical industry.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

Discovery & Development Drug Discovery

Marrying Up Proteins using Molecular Glues

| Angus Stewart

A husband-and-wife-led team used mass spec to identify new drugs that “glue” proteins together. We spoke to Aneika Leney about the project.

Discovery & Development Clinical Trials

Hope in the Fight Against Malaria

| Angus Stewart

Can a new malaria vaccine hold the key to reliable, durable protection?

Discovery & Development Drug Discovery

Nano-Origami Versus Infectious Agents

| Angus Stewart

It was by serendipity that Hendrik Dietz learned how to make a virus trap. Now, his team may be sitting on a new way to combat disease.

Business & Regulation Standards & Regulation

High Fines for High Prices

| Stephanie Sutton

Advanz Pharma is fined for substantially hiking the price of a generic drug.

Manufacture Standards & Regulation

Keeping Pace with the Plague

| Angus Stewart

Global regulators attended a virtual workshop on second generation COVID-19 vaccines – here’s what they talked about.

Manufacture Bioprocessing - Upstream & Downstream

Eliminating Bioconjugation Roadblocks

| Charlie Huang

To speed up vaccine development, we need to assess our bioconjugation approaches.

Manufacture Packaging

The Value of a Pack

| Adrian Collins

As trials change and adapt, so too must clinical packaging.

Business & Regulation Analytical Science

AI Reunites Pharma with Mother Nature

| Stephanie Sutton, Angus Stewart

Can AI facilitate a grand comeback for medicines sourced from Mother Nature?

Business & Regulation Biosimilars

What Lies Ahead for Biosimilars?

| Stephanie Sutton

Sandoz’s Pierre Bourdage talks to us about biosimilars and how uptake can be boosted.

Business & Regulation Business Practice

Think of the Patients

| Stephanie Sutton

GlaxoSmithKline’s Senior Vice President of US Oncology speaks about the pandemic and its impact on patients.

Business & Regulation Profession

Leadership Star

Sitting Down With… Andrew Moore, General Manager of Pfizer CentreOne.

Other issues of 2021